S&P 500
(0.00%) 5 187.67 points
Dow Jones
(0.44%) 39 056 points
Nasdaq
(-0.18%) 16 303 points
Oil
(1.08%) $79.23
Gas
(-1.04%) $2.18
Gold
(-0.33%) $2 316.60
Silver
(0.11%) $27.57
Platinum
(-0.26%) $985.85
USD/EUR
(0.12%) $0.931
USD/NOK
(0.04%) $10.90
USD/GBP
(0.12%) $0.800
USD/RUB
(0.19%) $91.62

Aktualne aktualizacje dla Metacrine, Inc. [MTCR]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Ostatnio aktualizowano20 birž. 2023 @ 22:11

-1.29% $ 0.581

Live Chart Being Loaded With Signals

Commentary (20 birž. 2023 @ 22:11):

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...

Stats
Dzisiejszy wolumen 83 889.00
Średni wolumen 52 473.00
Kapitalizacja rynkowa 25.48M
EPS $0 ( 2023-11-13 )
Last Dividend $0.580 ( 2023-06-21 )
Next Dividend $0 ( N/A )
P/E -0.564
ATR14 $0.0160 (2.75%)
Insider Trading
Date Person Action Amount type
2023-03-23 Klassen Preston Sell 842 211 Common Stock
2023-03-23 Klassen Preston Sell 842 211 Stock Option (right to buy)
2023-01-26 York Michael Sell 107 054 Common Stock
2023-01-26 Klassen Preston Sell 380 605 Common Stock
2022-12-21 Leonard Braden Michael Buy 120 099 Common Stock
INSIDER POWER
-17.12
Last 97 transactions
Buy: 12 877 287 | Sell: 12 262 808

Wolumen Korelacja

Długi: -0.64 (weak negative)
Krótki: 0.81 (strong)
Signal:(57.111) Same movement expected

Metacrine, Inc. Korelacja

10 Najbardziej pozytywne korelacje
LMRK0.865
KNBE0.855
AFBI0.834
OCAX0.833
IMRA0.83
AGFS0.83
QADA0.827
XOMAO0.824
EYEG0.821
STTK0.817
10 Najbardziej negatywne korelacje
GNUS-0.872
AGIL-0.858
CNEY-0.858
UTRS-0.857
TANH-0.855
MOTS-0.851
BLUE-0.849
PCSA-0.844
ADN-0.829
BJDX-0.827

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Metacrine, Inc. Korelacja - Waluta/Towar

The country flag -0.04
( neutral )
The country flag -0.52
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.68
( moderate )
The country flag 0.68
( moderate )

Metacrine, Inc. Finanse

Annual 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-2.40
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-2.40
FY 2020
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-1.436
FY 2019
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-1.520

Financial Reports:

No articles found.

Metacrine, Inc. Dividends

(Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0.580
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Metacrine, Inc. Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.580 2023-06-21
Last Dividend $0.580 2023-06-21
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.580 --
Avg. Dividend % Per Year 43.27% --
Score 4.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-05-08)
$1.160 Estimate 2.50 %
Dividend Stability
0.20 Very Poor
Dividend Score
4.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2023 $0.580 129.80%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Royal 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-0.7661.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.8351.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.150.80010.008.00[1 - 3]
quickRatioTTM13.400.80010.008.00[0.8 - 2.5]
cashRatioTTM9.851.50010.0010.00[0.2 - 2]
debtRatioTTM0.177-1.5007.06-10.00[0 - 0.6]
interestCoverageTTM-50.811.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-1.1202.00-0.373-0.747[0 - 30]
freeCashFlowPerShareTTM-1.1202.00-0.560-1.120[0 - 20]
debtEquityRatioTTM0.246-1.5009.01-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-3.341.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score-0.578

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.4001.000-0.1410[1 - 100]
returnOnEquityTTM-0.8352.50-6.68-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.1202.00-0.373-1.120[0 - 30]
dividendYielPercentageTTM99.761.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM-1.1202.00-0.373-0.747[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-0.413

Metacrine, Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej